Press release
Psoriasis Drugs Market Poised to Hit 20 Billion Dollars in 2025 as SNS Research Releases Comprehensive 2025-2035 Industry Outlook
"Psoriasis Drugs Market: 2025 - 2035 - Opportunities, Challenges, Strategies & Forecasts"
Global spending on psoriasis drugs is projected to approach 20 Billion dollars by the end of 2025, driven by rising disease prevalence, broader diagnosis, and a sustained shift toward high-efficacy immunology agents. The report examines how manufacturers are recalibrating strategy as treatment expectations continue to rise and patient preference shifts toward convenient, non-injectable options.
The 214-page study includes coverage of 50-plus development pipeline candidates and profiles 66 companies operating across biologics, oral systemics, and advanced topical modalities. The analysis outlines key factors that will determine market positioning through 2035, with emphasis on late-stage development trends, therapeutic class momentum, and evolving competitive pressures.
Key Findings in the Report:
Biologics remain the market's central growth driver. Interleukin inhibitors, particularly IL-17 and IL-23 agents such as Skyrizi and Tremfya, continue to anchor the category through strong efficacy and durable clearance rates.
Oral immunomodulators represent the next major commercial opportunity. Pipeline concentration on TYK2 and other targeted pathways reflects increasing demand for biologic-level outcomes without injections.
Biosimilar impact remains limited in the United States. Access constraints, contracting dynamics, and ongoing litigation have slowed adoption across TNF and IL-12/23 classes, extending the lifecycle of reference biologics.
Innovation is expanding across systemics and topicals. Selective JAK inhibitors, next-generation PDE4 agents, and advanced topical combinations are gaining traction as developers seek to improve adherence and long-term outcomes.
Industry consolidation continues to intensify. Acquisitions and platform partnerships underscore the strategic value of robust immunology portfolios and diversified modality positions.
The report concludes that long-term market leadership will depend on disciplined integration of clinical development progress with commercial execution, particularly in categories where convenience, durability of response, and differentiation remain decisive.
The full "Psoriasis Drugs 2025 Market" report, is available at: https://www.snsresearch.com/psoriasis-drugs-market-report-2025.html
SNS Research Group LLC
4227 Northern Pike, Pittsburgh, PA 15146
For enquiries, quotes, or additional information: info@snsintel.com
About SNS Research:
SNS Research is a U.S. based intelligence firm focused on the healthcare and pharmaceutical sectors. The company delivers independent market analysis, pipeline evaluations, and evidence-driven forecasts used by biopharmaceutical manufacturers, investors, government agencies, academic institutions, and regulatory organizations.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Drugs Market Poised to Hit 20 Billion Dollars in 2025 as SNS Research Releases Comprehensive 2025-2035 Industry Outlook here
News-ID: 4303429 • Views: …
More Releases from SNS Research
SNS Research has published its Pre-Filled Syringes 2023-2033 report.
SNS Research estimates that the market for pre-filled syringes will account for nearly $8.1 Billion in revenue by the end of 2023. Despite challenges relating to drug stability, manufacturing and competition from other drug delivery technologies, the market is poised for significant growth in the coming years.
A pre-filled syringe (PFS) is a single-dose disposable syringe which comes pre-filled with the substance to be injected. Pre-filled syringes constitute as one of…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
